[Abstract #1526] BRCA Testing Concordance with National Guidelines for Patients with Breast Cancer in Community Cancer Programs

Leigh Boehmer¹, Latha Shivakumar¹, Christine B. Weldon², Julia Rachel Trosman³, Stephanie A. Cohen⁴, Dawn Nixon⁴, Zohra Ali-Khan Catts⁵, Susan Miesfeldt⁶, Stephanie Wiryaman⁷, Lorraine Tafra⁸, Lisa Muto⁹, Natalie Fadrowski¹⁰, Melissa Hulvat¹¹, Tiana Pallister¹¹, Charles Hendrix Shelton¹²

1Association of Community Cancer Centers, Rockville, MD; 2Northwestern University Feinberg School of Medicine, Chicago, IL; ³Center for Business Models in Healthcare, Chicago, IL; ⁴St. Vincent Hospital, Indianapolis, IN; ⁵Christiana Care Health System, Newark, DE; ⁶Maine Medical Ctr Cancer Inst, Scarborough, ME; ⁷Maine Medical Center, Portland, ME; ⁸Anne Arundel Medical Ctr, Annapolis, MD; ⁹Cabell Huntington Hospital, Huntington, WV; ¹⁰University of Maryland Upper Chesapeake Health, Bel Air, MD; ¹¹Kalispell Regional Medical Center, Kalispell, MT; ¹²Vidant Health, Nags Head, NC

Current National Comprehensive Cancer Network® guidelines state that testing for highly penetrant breast/ovarian cancer genes is clinically indicated for women diagnosed with early onset (≤ 45 years), at later age (having met ethnic or family history criteria), or metastatic HER-2 negative breast cancer.

A recent Association of Community Cancer Centers (ACCC) survey (N = 95) showed that > 80% of respondents reported ≤ 50% testing rates among patients with breast cancer who met testing guidelines.

Given this disconnect, ACCC partnered with 15 community cancer programs to assess practice gaps and support interventions to improve genetic counseling/testing access.